Polyethylene glycol losenatide may not generally have much effect on the kidneys. Polyethylene glycol losenatide is a hypoglycemic drug, belonging to glucagon-like peptide-1 (GLP-1) receptor agonist. It is usually administered by subcutaneous injection and is metabolized mainly in the liver after entering the body, which may cause some liver toxicity, but generally does not affect kidney function. Polyethylene glycol losenatide may produce gastrointestinal adverse reactions such as nausea and abdominal distension, and patients need to be actively observed for changes in symptoms during treatment. The drug is contraindicated in people who are allergic to the components of the drug, patients with a personal past or family history of medullary thyroid carcinoma, and patients with type 2 multiple endocrine neoplasia syndrome. When using the drug for the treatment of diabetes, it is important to follow the doctor’s instructions for proper treatment.